摘要
目的:探索急性髓细胞白血病(AML)骨髓中Th17细胞及其相关因子在AML发生与发展中的作用。方法:选取初诊AML患者23例,另取25名健康志愿者为对照。采用流式细胞仪分别测初诊AML组、初诊AML组诱导缓解后、对照组骨髓中CD3^+ CD161^+ IL-17^+ IFN-γ^+ T细胞的比例。采用ELISA法检测初诊AML组、初诊AML组诱导缓解后、对照组骨髓液中血管内皮生长因子(VEGF)、IL-17浓度;对VEGF与IL-17进行相关性分析。结果:初诊AML组骨髓中CD3^+ CD161^+ IL-17^+ IFN-γ^+ T细胞的比例为(1.52±0.10)%,初诊AML组诱导缓解后CD3^+ CD161^+ IL-17^+ IFN-γ^+ T细胞的比例为(1.36±0.06)%,对照组骨髓中CD3^+ CD161^+ IL-17^+ IFN-γ^+ T细胞的比例为(0.22±0.04)%。初诊AML组VEGF浓度(254.08±24.34)pg/ml,IL-17浓度(20.24±3.82)pg/ml;初诊AML组诱导缓解后VEGF浓度(137.37±22.51)pg/ml,IL-17浓度(10.42±2.96)pg/ml;对照组骨髓液中VEGF浓度(125.98±14.96)pg/ml,IL-17浓度(10.59±2.87)pg/ml;VEGF与IL-17呈正相关。结论:Th17细胞具有促进AML发生与发展的作用。
Objective：To explore the role of Thl7 cells and related factors in acute myelold leukemia （AML）. Method：The ratio of CD3^＋ CD161^＋ IL-17^ ＋ IFN-γ^＋ T cells in bone marrow was examined by flow cytometry. Levels of VEGF,IL-17 in bone marrow were measured by ELISA. Result： The ratio of CD3^＋ CD161^＋ IL-17^＋ IFN-γ^＋ T cells in newly diagnosed AML patients was （1.52±0.10）% ,which was similar to the results of leukemia after CR （1. 36±0. 06）% （P〉0.05）,and was higher than that in control group （0.22±0.04）% （P〈0.05）. Levels of VEGF,IL-17 in newly diagnosed AML patients were （254.08±24.34） pg/ml, （20.24±3.82） pg/ml,which were significantly higher than those in leukemia after CR （137.37 ±22.51） pg/ml, （10.42 ± 2.96） pg/ml and control group （125.98±14.96） pg/ml,（10.59±2.87） pg/ml （P〈0.05）. And VEGF was positively related with IL-17. Conclusion：Th17 cells may play a promoting role in AML evolution.
出处
《临床血液学杂志》
CAS
2016年第3期389-391,共3页
Journal of Clinical Hematology
